Medtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.

Related Keywords

Dublin ,Ireland ,Ryan Weispfenning ,Rachel Murray ,Rossj Jr ,Jeffrey Popma ,Medtronic ,Exchange Commission ,Our Mission ,Renal Denervation ,Structural Heart ,Cardiovascular Portfolio ,Commercial Experience ,Tavr ,Aortic Stenosis ,Revolut ,Nited States Food And Drug Administration ,Coronary Arteries ,Aortic Valve Replacement ,